Roche posts results for two Phase 3 lebrikizumab asthma trials; Operetta 2 update on pediatric MS
Roche's registry updates this week cover completed lebrikizumab asthma studies with new results and continued progress in a pediatric multiple sclerosis trial comparing ocrelizumab to fingolimod.
Roche had a batch of clinical trial registry updates this week spanning lebrikizumab in asthma and ocrelizumab in pediatric multiple sclerosis.
- This completed Phase III trial evaluated lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist therapy alone, enrolling 313 participants.1 The primary outcome was change from baseline in pre-bronchodilator FEV1 at Week 12, a measure of how much air can be forcibly exhaled in one second.1 Results were first posted on 2026-07-17.
- This completed Phase III trial evaluated lebrikizumab in participants with asthma uncontrolled despite daily inhaled corticosteroid therapy and at least one second controller medication.2 The study enrolled 1081 participants.2 The primary outcome was the adjusted exacerbation rate of asthma during the 52-week placebo-controlled period, with exacerbation defined by new or worsening symptoms requiring systemic corticosteroids or hospitalization.2 Results were also first posted on 2026-07-17.
- This Phase III trial, active but not recruiting, compares ocrelizumab with fingolimod in children and adolescents aged 10 to under 18 years with relapsing-remitting multiple sclerosis.3 The study has enrolled 188 participants.3 The primary outcome is the protocol-defined annualized relapse rate.3 Results were first posted on 2026-07-15.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.